APCCC 2024 | The impact of novel imaging techniques on salvage radiotherapy decisions

Barbara Jereczek-Fossa, MD, PhD, University of Milan, Milan, Italy, discusses the role of novel imaging techniques such as prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) and 18F-fluciclovine in guiding treatment decisions for salvage radiotherapy. These advancements allow for the detection of macroscopic disease at lower prostate-specific antigen (PSA) levels, leading to possible changes in the indication for salvage therapy, including options like large field prosthetic bed plus lymph node area radiotherapy or metastasis-directed therapy. Ongoing trials aim to define the role of these imaging modalities in clinical decision-making. This interview took place at the 2024 Advanced Prostate Cancer Consensus Conference (APCCC) in Lugano, Switzerland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.